Completed PHASE2 INTERVENTIONAL 2-arm NCT00890305

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

Phase II Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease

Sponsor: Medivation, Inc.

Conditions Metastatic Colorectal Cancer

Interventions CT-011 FOLFOX

Updated 8 times since 2017 Last updated: Jun 10, 2015 Started: May 31, 2009 Primary completion: May 31, 2012 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Colorectal Cancer, this trial is completed. The trial is conducted by Medivation, Inc. and has accumulated 8 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medivation, Inc.

Data source: Medivation, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Chiclayo, Peru , Cluj-Napoca, Romania , Constanța, Romania , Craiova, Romania , Gabrovo, Bulgaria , Huntsville, United States , Iași, Romania , Lima, Peru , Lubbock, United States , Middletown, United States and 18 more locations